Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Paul Nghiem; Shailender Bhatia; Evan J Lipson; William H Sharfman; Ragini R Kudchadkar; Andrew S Brohl; Philip A Friedlander; Adil Daud; Harriet M Kluger; Sunil A Reddy; Brian C Boulmay; Adam Riker; Melissa A Burgess; Brent A Hanks; Thomas Olencki; Kari Kendra; Candice Church; Tomoko Akaike; Nirasha Ramchurren; Michi M Shinohara; Bob Salim; Janis M Taube; Erin Jensen; Mizuho Kalabis; Steven P Fling; Blanca Homet Moreno; Elad Sharon; Martin A Cheever; Suzanne L Topalian

doi:10.1136/jitc-2021-002478

Article info

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Authors

Paul Nghiem University of Washington / Fred Hutchinson Cancer Research Center, Seattle, Washington, USA PubMed articles Google scholar articles
Shailender Bhatia University of Washington / Fred Hutchinson Cancer Research Center, Seattle, Washington, USA PubMed articles Google scholar articles
Evan J Lipson Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy and Kimmel Cancer Center, Baltimore, Maryland, USA PubMed articles Google scholar articles
William H Sharfman Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy and Kimmel Cancer Center, Baltimore, Maryland, USA PubMed articles Google scholar articles
Ragini R Kudchadkar Emory University, Atlanta, Georgia, USA PubMed articles Google scholar articles
Andrew S Brohl Moffitt Cancer Center, Tampa, Florida, USA PubMed articles Google scholar articles
Philip A Friedlander Mount Sinai Medical Center, New York, New York, USA PubMed articles Google scholar articles
Adil Daud University of California San Francisco, San Francisco, California, USA PubMed articles Google scholar articles
Harriet M Kluger Yale University, New Haven, Connecticut, USA PubMed articles Google scholar articles
Sunil A Reddy Stanford University, Stanford, California, USA PubMed articles Google scholar articles
Brian C Boulmay Louisiana State University, New Orleans, Louisiana, USA PubMed articles Google scholar articles
Adam Riker Louisiana State University, New Orleans, Louisiana, USADepartment of Surgery, Anne Arundel Medical Center, Annapolis, Maryland, USADeCesaris Cancer Institute, Cancer Service Line, Luminis Health, Parole, Maryland, USA PubMed articles Google scholar articles
Melissa A Burgess University of Pittsburgh, Pittsburgh, Pennsylvania, USA PubMed articles Google scholar articles
Brent A Hanks Duke University Medical Center, Durham, North Carolina, USA PubMed articles Google scholar articles
Thomas Olencki Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA PubMed articles Google scholar articles
Kari Kendra Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA PubMed articles Google scholar articles
Candice Church University of Washington, Seattle, Washington, USA PubMed articles Google scholar articles
Tomoko Akaike University of Washington, Seattle, Washington, USA PubMed articles Google scholar articles
Nirasha Ramchurren Fred Hutchinson Cancer Research Center / Cancer Immunotherapy Trials Network, Seattle, Washington, USA PubMed articles Google scholar articles
Michi M Shinohara University of Washington, Seattle, Washington, USA PubMed articles Google scholar articles
Bob Salim Axio Research, LLC, Seattle, Washington, USA PubMed articles Google scholar articles
Janis M Taube Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy and Kimmel Cancer Center, Baltimore, Maryland, USA PubMed articles Google scholar articles
Erin Jensen Merck & Co Inc, Kenilworth, New Jersey, USA PubMed articles Google scholar articles
Mizuho Kalabis Merck & Co Inc, Kenilworth, New Jersey, USA PubMed articles Google scholar articles
Steven P Fling Fred Hutchinson Cancer Research Center / Cancer Immunotherapy Trials Network, Seattle, Washington, USA PubMed articles Google scholar articles
Blanca Homet Moreno Merck & Co Inc, Kenilworth, New Jersey, USA PubMed articles Google scholar articles
Elad Sharon National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, Maryland, USA PubMed articles Google scholar articles
Martin A Cheever Fred Hutchinson Cancer Research Center / Cancer Immunotherapy Trials Network, Seattle, Washington, USA PubMed articles Google scholar articles
Suzanne L Topalian Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy and Kimmel Cancer Center, Baltimore, Maryland, USA PubMed articles Google scholar articles

Citation

Nghiem P, Bhatia S, Lipson EJ, et al

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

Journal for ImmunoTherapy of Cancer 2021;9:e002478. doi: 10.1136/jitc-2021-002478

Online issue publication

May 06, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password